Key result
Prenatal treatment with flecainide and cardioversion increased cardiac conduction times in both twin fetuses, while heart rate variability showed opposing effects between the twins.
Why the study?
Does flecainide and cardioversion alter cardiac conduction times and HRV in a twin pregnancy with fetal supraventricular tachycardia?
Case Report (n=2)
Does flecainide and cardioversion alter cardiac conduction times and HRV in a twin pregnancy with fetal supraventricular tachycardia?
Magnetocardiography can be used to identify fetal arrhythmia and investigate the effects of antiarrhythmic treatment on the fetal conductive and autonomic nervous systems.
May support magnetocardiography for monitoring fetal antiarrhythmic effects; leaves open larger studies before clinical adoption in twin SVT.
We present a case of supraventricular tachycardia affecting one fetus in a twin pregnancy. Before and after treatment with flecainide and cardioversion, we examined conduction times and heart rate variability (HRV) in both twins on the basis of magnetocardiography. Cardiac conduction times increased in both fetuses but HRV showed opposing effects with a number of HRV measures. This case demonstrates that magnetocardiography not only enables identification of fetal arrhythmia, but also permits the investigation of the effects of antiarrhythmic treatment on the conductive system as well as on interaction with the autonomic nervous system.
No takes yet. Share an insight, caveat, or question.
Leeuwen et al. (2008) conducted a case report in Fetal supraventricular tachycardia in a twin pregnancy (n=2). Flecainide and cardioversion vs. Pre-treatment baseline was evaluated on Cardiac conduction times and heart rate variability (HRV). Prenatal treatment with flecainide and cardioversion increased cardiac conduction times in both twin fetuses, while heart rate variability showed opposing effects between the twins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: